Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
14%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_4
4
44%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 4Post-market surveillance
4(57.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Terminated(1)
Other(1)

Detailed Status

Completed7
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (42.9%)
Phase 44 (57.1%)

Trials by Status

completed778%
unknown111%
terminated111%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_4

ANTES B+ Clinical Trial

NCT06282861
completedphase_1

PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium

NCT03097380
unknownphase_4

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

NCT02546297
completedphase_4

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

NCT02567214
completed

Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

NCT02489981
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06282861Phase 4

ANTES B+ Clinical Trial

Terminated
NCT03097380Phase 1

PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium

Completed
NCT02546297Phase 4

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Unknown
NCT02567214Phase 4

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

Completed
NCT02489981

Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

Completed
NCT02263976Phase 1

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects

Completed
NCT02254174Phase 1

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Completed
NCT02172547

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

Completed
NCT00274079Phase 4

SPIRIVA in Ususal Care

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9